keyword
MENU ▼
Read by QxMD icon Read
search

CSII

keyword
https://www.readbyqxmd.com/read/28216284/new-risk-and-protective-factors-for-severe-hypoglycaemia-in-people-with-type-1-diabetes
#1
T Wohland, J D Holstein, O M Patzer, M Mende, T Tiemann, C Koch-Tessarek, P Kovacs, A Holstein
AIMS: To evaluate risk factors for severe hypoglycaemia (SH) in patients with type 1 diabetes (T1DM). METHODS AND RESULTS: Retrospective observational and comparative study. All SH occurring between 2007 and 2014 in a German population (Lippe-Detmold) were captured. Characteristics of patients with T1DM and SH were compared with a control group being equivalent concerning age, diabetes duration, HbA1c, comorbidity, and β-blocker treatment. SH was defined as a symptomatic event requiring treatment with intravenous glucose or glucagon administration and being confirmed by a blood glucose measurement of <2...
December 24, 2016: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/28208043/the-australasian-diabetes-data-network-first-national-audit-of-children-and-adolescents-with-type-1-diabetes
#2
Helen Phelan, Helen Clapin, Loren Bruns, Fergus J Cameron, Andrew M Cotterill, Jennifer J Couper, Elizabeth A Davis, Kim C Donaghue, Craig A Jefferies, Bruce R King, Richard O Sinnott, Elaine B Tham, Jerry K Wales, Timothy W Jones, Maria E Craig
OBJECTIVES: To assess glycaemic control, anthropometry and insulin regimens in a national sample of Australian children and adolescents with type 1 diabetes. DESIGN: Cross-sectional analysis of de-identified, prospectively collected data from the Australasian Diabetes Data Network (ADDN) registry. SETTING: Five paediatric diabetes centres in New South Wales, Queensland, South Australia, Victoria and Western Australia. PARTICIPANTS: Children and adolescents (aged 18 years or under) with type 1 diabetes of at least 12 months' duration for whom data were added to the ADDN registry during 2015...
February 20, 2017: Medical Journal of Australia
https://www.readbyqxmd.com/read/28162183/-influence-of-short-term-intensive-insulin-therapy-on-plasma-concentration-of-lipoprotein-associated-phospholipase-a-2-and-secretory-phospholipase-a-2-in-newly-diagnosed-type-2-diabetic-patients
#3
X H Lin, M T Xu, L F Mai, J Y Tang, X Y Wang, Y Li, L Yan
The aim of the study was to explore the effect and its clinical relevance of short-term intensive insulin treatment on plasma concentrations of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and secretory phospholipase A(2) (sPLA(2)) in newly diagnosed type 2 diabetes mellitus (T2DM). Ninety newly diagnosed T2DM patients were recruited and received continuous subcutaneous insulin infusion (CSII) for about 2 weeks. After CSII, sPLA(2) levels [173.78 (80.95, 278.09) μg/L] were significantly decreased compared with the levels before [219...
February 1, 2017: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/28161977/achieving-effective-glycaemic-control-using-an-insulin-micro-pump
#4
Peter Kelly
For those with type 1 diabetes mellitus (T1DM), a deranged blood glucose level can cause hypo/hyperglycaemic episodes and in the long term contribute to microvascular disease. Such outcomes can effect concordance with insulin management regimens and affect the patient's quality of life. A variety of insulin delivery methods are available, including continuous subcutaneous insulin infusion (CSII) via either a tethered or patch pump. Pumps have the potential to improve delivery, monitoring and adjustment of insulin regimens, thus freeing patient's time and affording more control of their disease...
February 2, 2017: British Journal of Community Nursing
https://www.readbyqxmd.com/read/28156154/insulin-timing-a-patient-centered-approach-to-improve-control-in-type-1-diabetes
#5
Elizabeth Duran-Valdez, Mark R Burge, Paula Broderick, Lynda Shey, Virginia Valentine, Ronald M Schrader, David S Schade
PURPOSE OF STUDY: The goal of insulin therapy in type 1 diabetes is to reduce A1C to ≤ 7.0% with minimal hypoglycemia. We investigated the possibility that "insulin timing" would improve A1C without incurring severe hypoglycemia in volunteers with T1D over a 6 month observation period. METHODS: Forty healthy adult volunteers with T1D were randomly assigned for six months to one of two groups: a control group or an insulin timing group. The primary endpoint was the difference in A1C between the two groups...
February 3, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28154987/striving-for-control-lessons-learned-from-a-successful-international-type-1-diabetes-youth-challenge
#6
Olga Kordonouri, Andriani Vazeou, Mauro Scharf, Martina Würsig, Tadej Battelino
AIMS: To demonstrate whether young people with T1D using modern insulin treatment and CGM could successfully participate in extreme sport activity while maintaining good glycemic control. METHODS: The challenge took place in Crete/Greece over 4 days combining a long-distance trek of different levels of severity with final destination the summit of the White Mountains at 2080 m. Eleven participants (5/6 female/male, age 18.2 ± 1.3 years, T1D duration 7.9 ± 3...
February 2, 2017: Acta Diabetologica
https://www.readbyqxmd.com/read/28098839/continuous-glucose-monitoring-enables-the-detection-of-losses-in-infusion-set-actuation-lisas
#7
Daniel P Howsmon, Faye Cameron, Nihat Baysal, Trang T Ly, Gregory P Forlenza, David M Maahs, Bruce A Buckingham, Juergen Hahn, B Wayne Bequette
Reliable continuous glucose monitoring (CGM) enables a variety of advanced technology for the treatment of type 1 diabetes. In addition to artificial pancreas algorithms that use CGM to automate continuous subcutaneous insulin infusion (CSII), CGM can also inform fault detection algorithms that alert patients to problems in CGM or CSII. Losses in infusion set actuation (LISAs) can adversely affect clinical outcomes, resulting in hyperglycemia due to impaired insulin delivery. Prolonged hyperglycemia may lead to diabetic ketoacidosis-a serious metabolic complication in type 1 diabetes...
January 15, 2017: Sensors
https://www.readbyqxmd.com/read/28055230/improved-postprandial-glycemic-control-with-faster-acting-insulin-aspart-in-patients-with-type-1-diabetes-using-continuous-subcutaneous-insulin-infusion
#8
Bruce W Bode, Joseph A Johnson, Liselotte Hyveled, Søren C Tamer, Marek Demissie
BACKGROUND: Faster aspart is insulin aspart (IAsp) in a new formulation, which in continuous subcutaneous insulin infusion (CSII) in subjects with type 1 diabetes has shown a faster onset and offset of glucose-lowering effect than IAsp. METHODS: This double-blind, randomized, crossover active-controlled trial compared 2-h postprandial plasma glucose (PPG) response, following 2 weeks of CSII with faster aspart or IAsp. Primary endpoint: mean change in PPG 2 h after a standardized meal test (ΔPGav,0-2h)...
January 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28052468/young-people-with-type-1-diabetes-mellitus-attitudes-perceptions-and-experiences-of-diabetes-management-and-continuous-subcutaneous-insulin-infusion-therapy
#9
Lin Perry, Steven James, Katharine Steinbeck, Janet Dunbabin, Julia Lowe
RATIONALE, AIMS, AND OBJECTIVES: Continuous subcutaneous insulin infusion (CSII; insulin pump) use is increasing. However, there is little information about how this technology is used compared with other insulin delivery methods (ie, injections) by young people with type 1 diabetes mellitus in Australia. This study explored young people's attitudes, perceptions, and experiences with diabetes management comparing those using with those not using CSII, and proportions likely to transition to adult services requiring initiation and/or support for CSII use...
January 4, 2017: Journal of Evaluation in Clinical Practice
https://www.readbyqxmd.com/read/28004007/clinical-efficacy-of-two-different-methods-to-initiate-sensor-augmented-insulin-pumps-a-randomized-controlled-trial
#10
Jesus Moreno-Fernandez, Francisco Javier Gómez, Maria Ángeles Gálvez Moreno, Justo P Castaño
Aim. To analyze clinical effect of a novel approach to initiate sensor-augmented insulin pumps in type 1 diabetes mellitus (T1DM) patients through early real-time continuous glucose monitoring (RT-CGM) initiation. Methods. A 26-week pilot study with T1DM subjects randomized (1 : 1) to start RT-CGM three weeks before continuous subcutaneous insulin infusion (CGM pre-CSII) or adding RT-CGM three weeks after continuous subcutaneous insulin infusion (CGM post-CSII). Results. Twenty-two patients were enrolled with a mean age of 36...
2016: Journal of Diabetes Research
https://www.readbyqxmd.com/read/27995593/exenatide-add-on-to-continuous-subcutaneous-insulin-infusion-therapy-reduces-bolus-insulin-doses-in-patients-with-type-2-diabetes-a-randomized-controlled-open-label-trial
#11
Feng-Fei Li, Lanlan Jiang, Liyuan Fu, Hong-Hong Zhu, Peihua Zhou, Danfeng Zhang, Xiao-Fei Su, Jin-Dan Wu, Lei Ye, Jian-Hua Ma
INTRODUCTION: The objective of this study was to investigate the effect of adding exenatide to continuous subcutaneous insulin infusion (CSII) therapy on the precise insulin doses required by type 2 diabetic patients to maintain glycemic control. METHODS: This was a single-center, randomized, controlled, open-label trial. Uncontrolled T2D patients were recruited between March 2010 and November 2011 at Nanjing First Hospital, China. Subjects were randomly assigned (1:1) to either an exenatide add-on to CSII group or a CSII therapy only (i...
February 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/27972334/health-economic-analysis-of-the-use-of-sensor-augmented-pump-with-predictive-suspend-function-sap-therapy-in-sweden-compared-to-insulin-pump-therapy-alone-csii-in-type-1-diabetic-patients
#12
S Roze, A Gherardi, S de Portu, J Jendle
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27881128/effect-of-intensive-insulin-treatment-on-plasma-levels-of-lipoprotein-associated-phospholipase-a2-and-secretory-phospholipase-a2-in-patients-with-newly-diagnosed-type-2-diabetes
#13
Xiu-Hong Lin, Ming-Tong Xu, Jv-Ying Tang, Li-Fang Mai, Xiao-Yi Wang, Meng Ren, Li Yan
BACKGROUND: China has the highest absolute disease burden of diabetes worldwide. For diabetic patients, diabetes-related vascular complications are major causes of morbidity and mortality. The roles of lipoprotein-associated phospholipase A2 (Lp-PLA2) and secretory phospholipase A2 (sPLA2) as inflammatory markers have been recently evaluated in the pathogenesis of both diabetes and atherosclerosis. We aimed to determine the mechanism through which patients with newly diagnosed type 2 diabetes gain long-term vascular benefit from intensive insulin therapy by evaluating the change in Lp-PLA2 and sPLA2 levels after early intensive insulin treatment and its relevance with insulin resistance and pancreatic β-cell function...
November 23, 2016: Lipids in Health and Disease
https://www.readbyqxmd.com/read/27860498/clinical-outcomes-after-1-year-of-augmented-insulin-pump-therapy-in-patients-with-diabetes-in-a-specialized-diabetes-center-in-medell%C3%A3-n-colombia
#14
Alex Ramirez-Rincon, Jaime Hincapie-García, Claudia Monsalve Arango, Natalia Aristizabal, Estefany Castillo, Gloria Hincapie, Eliana Zapata, Diana Paola Cuesta, Maria Delgado, Veronica Abad, Jose Luis Torres, Andres Palacio, José Fernando Botero
BACKGROUND: Type 1 diabetes can be difficult to control. Augmented pump therapy (CSII-rtCGM) has become an important tool for controlling blood glucose and decreasing hypoglycemia. METHODS: Describe the results 1 year after starting CSII-rtCGM in patients with diabetes in Medellín, Colombia. This is an observational, retrospective study. Patients with type 1 and type 2 diabetes started on CSII-rtCGM between January 2008 and June 2015 were included. Qualitative variables were analyzed as absolute or relative frequencies...
November 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27846929/-ccafu-french-national-guidelines-2016-2018-on-testicular-germ-cell-tumors
#15
X Durand, A Fléchon, T Murez, L Rocher, P Camparo, N Morel-Journel, P-H Savoie, L Ferretti, P Sèbe, A Méjean
INTRODUCTION: The purpose of the oncologic comitee of the french association of urology was to establish guidelines proposed by the external genital organ group, for the diagnosis, treatment and follow-up of the germ cell tumours of the testis. MATERIAL AND METHODS: The multidisciplinary working group studied 2013 guidelines, exhaustively reviewed the literature, and evaluated references and their level of proof in order to attribute grades of recommandation. RESULTS: The initial workup of testicular cancer is based on clinical, laboratory (AFP, total hCG, LDH) and imaging assessment (scrotal ultrasound and chest, abdomen and pelvis computed tomography)...
November 2016: Progrès en Urologie
https://www.readbyqxmd.com/read/27824066/a-novel-insulin-glucose-model-after-a-mixed-meal-test-in-patients-with-type-1-diabetes-on-insulin-pump-therapy
#16
Luca Marchetti, Federico Reali, Marco Dauriz, Corinna Brangani, Linda Boselli, Giulia Ceradini, Enzo Bonora, Riccardo C Bonadonna, Corrado Priami
Current closed-loop insulin delivery methods stem from sophisticated models of the glucose-insulin (G/I) system, mostly based on complex studies employing glucose tracer technology. We tested the performance of a new minimal model (GLUKINSLOOP 2.0) of the G/I system to characterize the glucose and insulin dynamics during multiple mixed meal tests (MMT) of different sizes in patients with type 1 diabetes (T1D) on insulin pump therapy (continuous subcutaneous insulin infusion, CSII). The GLUKINSLOOP 2.0 identified the G/I system, provided a close fit of the G/I time-courses and showed acceptable reproducibility of the G/I system parameters in repeated studies of identical and double-sized MMTs...
November 8, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27793354/continuous-subcutaneous-insulin-infusion-as-an-effective-method-of-desensitization-therapy-for-diabetic-patients-with-insulin-allergy-a-4-year-single-center-experience
#17
Tao Yuan, Weigang Zhao, Lianglu Wang, Yingyue Dong, Naishi Li
PURPOSE: This article summarizes our experiences in the application of continuous subcutaneous insulin infusion (CSII) as a method of rapid desensitization therapy for diabetic patients with insulin allergy that was subsequently switched to a regimen of multiple-dose injections for long-term insulin therapy. METHODS: The clinical data of 11 diabetic patients with insulin allergy in Peking Union Medical College Hospital from April 1, 2008, through December 31, 2011, were retrospectively analyzed...
October 25, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27787387/effects-of-saxagliptin-add-on-therapy-to-insulin-on-blood-glycemic-fluctuations-in-patients-with-type-2-diabetes-a-randomized-control-open-labeled-trial
#18
RANDOMIZED CONTROLLED TRIAL
Feng-Fei Li, Lan-Lan Jiang, Reng-Na Yan, Hong-Hong Zhu, Pei-Hua Zhou, Dan-Feng Zhang, Xiao-Fei Su, Jin-Dan Wu, Lei Ye, Jian-Hua Ma
BACKGROUND: To investigate whether saxagliptin add-on therapy to continuous subcutaneous insulin infusion (CSII) further improve blood glycemic control than CSII therapy in patients with newly diagnosed type 2 diabetes (T2D). METHODS: This was a single-center, randomized, control, open-labeled trial. Newly diagnosed T2D patients were recruited between February 2014 and December 2015. Subjects were divided into saxagliptin add-on therapy to CSII group (n = 31) and CSII therapy group (n = 38)...
October 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27765490/impact-of-diabetes-education-on-type-1-diabetes-mellitus-control-in-children
#19
Daniel E Alonso Martín, M Belén Roldán Martín, M Ángeles Álvarez Gómez, Rosa Yelmo Valverde, María Martín-Frías, Milagros Alonso Blanco, Raquel Barrio Castellanos
INTRODUCTION: Diabetes education is an essential tool to achieve treatment objectives in type1 diabetes mellitus (T1DM). The aim of this study was to determine if understanding of diabetes by caregivers/patients or sociodemographic factors affect blood glucose control in children and adolescents with T1DM. PATIENTS AND METHODS: The level of knowledge of 105 caregivers of children and adolescents with T1DM was assessed using a survey adapted to the type of treatment used (multiple dose insulin [MDI] or continuous subcutaneous insulin infusion [CSII])...
December 2016: Endocrinología y Nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición
https://www.readbyqxmd.com/read/27735893/-neurological-complications-in-patients-with-diabetes-mellitus-type-1-treated-with-different-methods-of-insulinotherapy
#20
N F Shimkina, Yu G Nad', E R Barantsevich
: The study aims to examine the neurological complications of patients with type 1 diabetes treated with different methods of insulin therapy. MATERIAL AND METHODS: Thirty-four patients, aged from 18 to 40 years, with diabetes mellitus type 1 receiving insulinotherapy, with a duration of the disease 14.25±9.25 years, have been examined. By the time of the study the patients of the first group have been treated with continuous subcutaneous insulin infusion therapy (CSII) for 4...
2016: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
keyword
keyword
50725
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"